Rollo Capital Management ("RCM") is a Boston-based investment firm established in January 2008 and focused on industrial sectors, with an emphasis on materials, capital goods, chemicals, technology, automotive, energy and aerospace.
RCM is the manager and advisor of CIP (Change in Progress), LP, an investment partnership pursuing medium and long-term investment strategies in publicly-listed industrial companies with an emphasis on change and innovation and with a value-based philosophy.
RCM is also the manager of RCV I, LLC, an investment vehicle focused on early-stage innovative companies in the areas of materials and automation. Portfolio investments include: Gelesis (NYSE: GLS), enEvolv (acquired by Zymergen; NYSE: ZY), Continuus Pharmaceuticals (www.continuuspharma.com), PanTher Therapeutics (www.panthertx.com), Pearl Bio (pearlbio.com).
Company Details
- Founded
- -
- Address
- Boston, Us
- Industry
- Financial Services
- NAICS
-
Finance and InsuranceMonetary Authorities-Central Bank
- Website
- rollocapital.com
- HQ
- Boston
Rollo Capital Management Questions
Rollo Capital Management's website is rollocapital.com
Rollo Capital Management's LinkedIn profile is https://www.linkedin.com/company/rollo-capital
Rollo Capital Management's industry is
Financial Services
Rollo Capital Management's top competitors are
Numia S.p.a.,
Park Street School,
Arena Capital Partners,
Alpine Investors,
Evolve Academy,
Westview,
Arcadia Ventures,
Exeter22,
Chinatown Main Street,
Blue Pine Partners, Llc.
Rollo Capital Management's categories are Financial Services
Rollo Capital Management's founding year is 2008
